Overdoses Dropped When Prescribing Fell for Pregabalin

By Pat Anson

Prescription opioids get most of the attention, but there’s another class of medication that is often associated with misuse, dependence and overdose: gabapentinoids. 

Originally developed to treat epileptic seizures, gabapentinoids like pregabalin (Lyrica) and gabapentin (Neurontin) are often prescribed off-label as an alternative to opioids, even though there is little evidence to support their use as analgesics. Sales of Lyrica and Neurontin tripled over a decade ago, just as prescriptions for opioids became harder to get in the U.S. and other countries.

That overprescribing led to problems around the world. In the UK, about a third of drug deaths in 2022 involved a gabapentinoid; while in Australia, overdoses involving pregabalin increased by 54% between 2005 and 2016. 

Gabapentinoids alone rarely cause death. But when taken along with opioids, benzodiazepines, anti-depressants or muscle relaxants, gabapentinoids heighten the risk of abuse and overdose.

A new study in Australia shows what can happen when pregabalin prescribing is reduced, and doctors and patients are better educated about the drug’s potential risks. Overdoses in Australia involving pregabalin have fallen 47% since stricter scheduling was adopted and boxed warnings were added to prescription labels.  

“After many years of escalating pregabalin use and overdose in Australia, rates appear to have plateaued and started to decline since 2018,” wrote lead author Rose Cairns, PhD, an Associate Professor in the School of Pharmacy at University of Sydney, in The BMJ.  

“While our findings are positive, pregabalin use and overdose remain high, with dispensing rates still far outstripping what would be expected if pregabalin was prescribed for approved indications alone. Therefore, ongoing monitoring is needed and we should consider further interventions, including additional scheduling restrictions.”

Cairns and her colleagues say caution is warranted because almost half of Australians taking pregabalin also use opioids. About 13% of patients prescribed pregabalin are considered at high risk of abuse. 

Pregabalin is FDA-approved to treat diabetic nerve pain, fibromyalgia, nerve pain from shingles and spinal cord injuries; while gabapentin is approved to treat epilepsy and shingles pain. Both drugs are also widely prescribed off label to treat back pain, depression, migraine and post-operative pain. Studies have estimated that gabapentin is prescribed off-label up to 95% of the time.  

"Despite this relatively narrow range of approved indications, gabapentinoids are considered 'blockbuster' drugs," wrote Cairns. "High-income countries have the highest rates of gabapentinoid consumption, while low- and middle-income countries have had the highest consumption growth in recent years. Most of this consumption is driven by off-label use for non-registered indications." 

Patients have long complained that gabapentinoids are ineffective for pain, and have side effects like brain fog, dizziness, weight gain and mood disorders. Recent research has also linked gabapentin to dementia.

A recent study of Medicaid patients found that being prescribed gabapentinoids for acute low back pain increases the risk of overdosing or developing opioid use disorder nearly as much as taking opioids. Despite the documented risks of taking them together, nearly 60% of U.S. patients on long-term opioid therapy are also prescribed gabapentinoids.